Progress or lack of progress in hospitalized heart failure

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank Fumiko Inoue for her excellent technical assistance with the preparation of this manuscript.

Financial & competing interests disclosure

J Butler is a consultant for Stemedica, Medtronic, Bayer, Novartis, Amgen, Gambro, Harvest, Celladon, Ono, and Trevena. GC Fonarow has received research grants from NHLBI, AHRQ and is a consultant for Novartis, Gambro and Medtronic. M Gheorghiade is a consultant for Abbott Laboratories, Astellas, Astra Zeneca, Bayer Schering Pharma AG, CorThera, Inc, Cytokinetics, Inc, Debiopharm SA, Errekappa Terapeutici (Milan, Italy), GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau and Solvay Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.